Skip to content
Clinical Trials – home

Hospital Universitario Quironsalud Madrid

Verified siteinfo

Spain Calle De Diego De Velazquez 1, 28223 Pozuelo De Alarcon, Spain

  • 106 trials recruiting
  • Non-small cell lung cancer · Neoplasm · Plasma cell myeloma
  • Adults and children

About Specializations

Hospital Universitario Quironsalud Madrid in Pozuelo De Alarcon, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Neoplasm, Plasma cell myeloma, Neoplasm malignant, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Medicine and Airway Disease

At Hospital Universitario Quironsalud Madrid, the Servicio de Neumología is running studies across key respiratory tract diseases, focusing on conditions such as chronic obstructive pulmonary disease, bronchiectasis, severe asthma, and respiratory syncytial virus prevention in vulnerable children. These trials are mainly designed to improve symptom control, reduce flare-ups, and evaluate new treatment options for people living with chronic lung disease.

  • Chronic obstructive pulmonary disease and long-term control of exacerbations
  • Bronchiectasis and maintenance treatment after prior study participation
  • Severe asthma with eosinophilic inflammation and add-on therapy
  • Respiratory syncytial virus prevention in infants and children at higher risk

This research also reflects a strong interest in practical outcomes that matter to patients, such as breathing stability, fewer hospital visits, and better day-to-day quality of life.

Oncology and Hematologic Malignancies

A major part of the site’s clinical research is centered on neoplasms, especially lung cancer, breast cancer, bladder cancer, melanoma, and a wide range of lymphomas and other blood cancers. These trials are exploring new immunotherapies, targeted approaches, and combination strategies to improve tumor control and extend survival in both newly diagnosed and previously treated disease.

  • Solid tumors including lung, breast, bladder, prostate, and head and neck cancers
  • Hematologic cancers such as follicular lymphoma, diffuse large B-cell lymphoma, and multiple myeloma
  • Studies in relapsed or refractory disease to find better treatment options
  • Trials evaluating whether new combinations can improve response and survival outcomes

The oncology portfolio at Hospital Universitario Quironsalud Madrid shows broad activity in both common and harder-to-treat cancers, with an emphasis on testing therapies that may offer more durable benefit.

Cardiometabolic and Metabolic Health

The site is also involved in research on cardiovascular diseases and nutritional and metabolic diseases, including atherosclerotic cardiovascular disease, hypercholesterolemia, obesity, overweight, type 2 diabetes, and non-alcoholic steatohepatitis. These studies are aimed at preventing major cardiovascular events, improving lipid and glucose control, and understanding how metabolic disease can be managed more effectively over time.

  • Prevention of heart attacks, stroke, and other major cardiovascular events
  • Lowering LDL cholesterol and improving lipid-related risk
  • Weight-related conditions, including obesity and overweight
  • Metabolic liver disease such as non-alcoholic steatohepatitis

This area combines prevention-focused research with treatment studies for people already living with cardiometabolic risk factors.

Immunology, Skin Disease, and Inflammatory Conditions

Clinical trials at the site also cover immune system diseases and skin and connective tissue diseases, with work in atopic dermatitis, prurigo nodularis, and other inflammatory conditions. The goal is to test therapies that can better relieve itching, reduce skin inflammation, and improve visible symptoms and comfort for patients with chronic immune-mediated disease.

  • Atopic dermatitis and eczema-related disease control
  • Prurigo nodularis with a focus on itch relief and skin improvement
  • Inflammatory conditions where symptom reduction is a key outcome
  • Research on new immune-targeted treatment approaches

These studies add an important dermatology and immunology dimension to the research profile of Hospital Universitario Quironsalud Madrid.

Neurology, Pain, and Musculoskeletal Research

Another active area includes nervous system diseases and musculoskeletal diseases, with studies in migraine, early Parkinson’s disease, multiple sclerosis, diabetic peripheral neuropathic pain, and knee osteoarthritis pain. These trials are generally focused on improving symptom relief, preserving function, and assessing whether new treatments can better support long-term daily living.

  • Migraine treatment and safety in pediatric and adult settings
  • Early Parkinson’s disease and disease-modifying research
  • Multiple sclerosis with emphasis on long-term tolerability
  • Neuropathic and joint pain, including diabetic nerve pain and osteoarthritis

This mix of neurological and pain-related studies broadens the site’s research beyond major organ disease into conditions that strongly affect mobility and quality of life.

Autoimmune, Blood, and Other Specialized Research

The trial portfolio also includes hemic and lymphatic diseases and selected complex inflammatory disorders, such as warm autoimmune hemolytic anemia and other immune-mediated blood conditions. In addition, the site participates in studies that look at vaccine responses, infection prevention, and broader health-related questions linked to public health and metabolism.

  • Autoimmune blood disorders and anemia-related outcomes
  • Lymphoid and other hematologic conditions with limited treatment options
  • Vaccine and infection-prevention research
  • Broader studies tied to public health and metabolic processes

Together, these projects show a diverse research environment at the Hospital Universitario Quironsalud Madrid, with studies spanning chronic disease management, cancer care, immune disorders, and prevention.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle De Diego De Velazquez 128223 Pozuelo De AlarconSpain
Recruiting now
106 trials
Conditions studied
174
Partner status
Verified site

More sites in Pozuelo De AlarconSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

299 clinical trials

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Summit Therapeutics Inc.

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Obesity+1

Recruiting

A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.